



BC PharmaCare Newsletter

May 13, 2015 Edition 15-005

Published by the Medical Beneficiary and Pharmaceutical Services Division to provide information for British Columbia’s health care providers

QuickLinks

PharmaCare Enrollment Deadline May 31	1
Blood Glucose Test Strips Claims—Reminder	2
Digital Copies Only—Newsletter	2
Benefits	2
Non-Benefits.....	2

PHARMACARE ENROLLMENT DEADLINE MAY 31!

As announced in the November 27, 2014, [PharmaCare Newsletter 14-009](#), current providers were advised to submit their enrollment applications to the Ministry of Health (through Health Insurance BC) by March 1, 2015, to ensure sufficient time for processing.

As of April 30, we still have not received completed applications for all current providers.

If you have not yet submitted your application, or are resubmitting, please fully complete and submit all required documentation **immediately** if you wish to continue to be able to submit claims to PharmaCare after May 31, 2015.

IMPORTANT:

- Applications must be sent to the HIBC address indicated on the last page of the Provider Enrollment form. Sending applications directly to the Ministry will result in processing delays.
- If you have already sent the application to HIBC via **fax**, there is no need to **mail** a copy as well.

If you have already applied for enrollment

To date, Health Insurance BC has received and the Ministry has approved applications for the majority of sites. Approved providers will be receiving Welcome Packages in the near future.

The use of PharmaNet is not intended as a substitute for professional judgment.
Information on PharmaNet is not exhaustive and cannot be relied upon as complete.

The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient.
Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.

BLOOD GLUCOSE TEST STRIPS CLAIMS—REMINDER

Ensuring your patient is in the correct quantity limit category

A patient's quantity limit is based on the diabetes treatment they currently receive. If there is a change in their treatment, there will be a corresponding change in their quantity limit. For this reason, if a patient is picking up both diabetes drugs and strips, please remember to enter the drug claim **first** to make sure the patient is in the correct quantity limit category.

DIGITAL COPIES ONLY—NEWSLETTER

Subscribe!

Would you like to receive an e-mail notification when a new PharmaCare Newsletter or PharmaNet Bulletin is posted on our website? Visit our [Subscription Service page](#) for more information.

June 1, 2015, will be the last mailing of the print version of the PharmaCare newsletter. The digital edition will continue to be posted on the PharmaCare website in an easy-to-print PDF format.

Please note that approved providers are required to abide by PharmaCare policies as published in PharmaCare policy manuals and in PharmaCare Newsletters and PharmaNet Bulletins.

Sign up to receive an e-mail whenever a newsletter or bulletin is published. Visit the PharmaCare Newsletter page at www.gov.bc.ca/pharmacarenewsletter today to subscribe.

BENEFITS

Special Authority Coverage of ticagrelor (Brilinta®) for the Treatment of Acute Coronary Syndrome

Effective **April 14, 2015**, PharmaCare Special Authority (SA) coverage for [ticagrelor](#) for the treatment of Acute Coronary Syndrome has changed. For detailed criteria, visit www.gov.bc.ca/pharmacarespecialauthority and select the drug from the "List of Limited Coverage and Non-Reference Drugs requiring Special Authority Approval."

Coverage for this drug is subject to the rules of a patient's PharmaCare plan, including any annual deductible requirement. Retroactive coverage cannot be provided for prescriptions filled before Special Authority approval is in place.

NON-BENEFITS

The following products have been reviewed and will not be added as benefits under PharmaCare.

DIN	DRUG NAME
02322374	aripiprazole (Abilify®) 2 mg oral tablet for major depressive disorder
02322382	aripiprazole (Abilify®) 5 mg oral tablet for major depressive disorder
02322390	aripiprazole (Abilify®) 10 mg oral tablet for major depressive disorder
02322404	aripiprazole (Abilify®) 15 mg oral tablet for major depressive disorder
02322412	aripiprazole (Abilify®) 20 mg oral tablet for major depressive disorder
02322455	aripiprazole (Abilify®) 30 mg oral tablet for major depressive disorder